Enrasentan, an antagonist of endothelin receptors

Cardiovascular Drug Reviews

Volumn 21, Issue 1, 2003, Pages 1-16

  Cosenzi, Alessandro ^a,b  

^a UNIVERSITY OF TRIESTE   (Italy)

^b UNIVERSITY OF TRIESTE   (Italy)

Author keywords

Endothelin antagonists; Endothelin receptors; Endothelins; Enrasentan; Heart failure; Hypertension

Indexed keywords

1,4 DIHYDRO 5 METHOXYCARBONYL 2,6 DIMETHYL 4 (3 NITROPHENYL) 3 PYRIDINECARBOXYLIC ACID ANHYDRIDE; 3 (2 CARBOXYMETHOXY 4 METHOXYPHENYL) 1 (3,4 METHYLENEDIOXYPHENYL) 5 PROPOXY 2 INDANCARBOXYLIC ACID; ANTIHYPERTENSIVE AGENT; ATRASENTAN; BOSENTAN; CGS 27830; CLAZOSENTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; ENDOTHELIN; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR; ENDOTHELIN B RECEPTOR; ENDOTHELIN RECEPTOR ANTAGONIST; ENRASENTAN; HYDRALAZINE; NITRIC OXIDE; PHOSPHORAMIDON; PROSTACYCLIN; SARALASIN; SULFONAMIDE; UNCLASSIFIED DRUG;

BINDING AFFINITY; CELL PROLIFERATION; DIABETES MELLITUS; DRUG RECEPTOR BINDING; ENDOTHELIUM CELL; EXTRACELLULAR MATRIX; HEART FAILURE; HEART FIBRILLATION; HEART VENTRICLE HYPERTROPHY; HUMAN; HYPERINSULINEMIA; HYPERTENSION; LIVER CIRRHOSIS; NONHUMAN; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RECEPTOR BLOCKING; REVIEW; STROKE; VASCULAR SMOOTH MUSCLE; VASOCONSTRICTION;

EID: 0037255207     PISSN: 08975957     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1527-3466.2003.tb00102.x     Document Type: Review

References (81)

1. Alioglu Z, Orem A, Bulbul I, Boz C, Ozmenoglu M, Vanizor B. Evaluation of plasma ET-1 levels in patients with cerebral infarction. Angiology 2002;53(1):77-82.
2. Bakaiis GL, Re RN. Endothelin modulates angiotensin II-induced mitogenesis of human mesangial cells. Am J Physiol 1993;264:F937-F942.
3. Barone FC, White RF, Elliott JD, Feuerstein GZ, Ohlstein EH. The endothelin receptor antagonist SB 217242 reduces cerebral focal ischemic brain injury. J Cardiovasc Pharmacol 1995;26(Suppl 3):S404-S407.
4. Benigni A, Colosio V, Brena C, Bruzzi I, Bertani T, Remuzzi G. Unselective inhibition of endothelin receptors reduces renal dysfunction in experimental diabetes. Diabetes 1998;47(3):450-456.
5. Benigni A, Corona D, Maffi R, Benedetti G, Zoja C, Remuzzi G. Renoprotective effect of contemporary blocking of angiotensin II and ET-1 in rats with membranous nephropathy. Kidney Int 1998;54(2):646-647.
6. Best of the ACC Scientific Session 2001. Rev Cardiovasc Med 2001;2(3):143-159.
7. Bhardwaj A, Wu Y, Hurn PD, Kirsch JR, Traystman RJ. Administration of selective endothelin receptor type A antagonist Ro 61-1790 does not improve outcome in focal cerebral ischemia in cat. J Cereb Blood Flow Metab 2000;20(3):499-504.
8. Boffa JJ, Tharaux PL, Dussaule JC, Chatziantoniou C. Regression of renal vascular fibrosis by endothelin receptor antagonism. Hypertension 2001;37(Part 2):490-496.
9. Brooks DP, DePalma PD. Unmasking of ET-1-induced natriuresis and renal vasodilation in the dog by enrasentan (SB 217242). J Cardiovasc Pharmacol 2000;36(5,Suppl 1):S346-S347.
10. Cao LQ, Banks RO. Cardiorenal actions of endothelin. 1. Effects of converting enzyme inhibition. Life Sci 1990;46:577-583.
11. Chandra S, Sarkar S, Elliot JD, Ohlstein EH. Application of magnetic resonance imaging for evaluation of the efficacy of SB 217242 in neointimal formation. J Cardiovasc Pharmacol 1998;31(Suppl 1):S317-S319.
12. Chin MH, Cioffi CL, Garay M et al. The usual binding properties of endothelin receptor antagonists CGS 27830 distinguishes receptor/agonist interactions. J Pharmacol Exp Ther 1996;276:74-83.
13. Clozel M, Breu V, Gray et al. Pharmacological characterization of bosentan, a new potent orally active nonpeptide endothelin receptor antagonist. J Pharmacol Exp Ther 1994;270:228-235.
14. Cosenzi A, Bernobich E, Bonavita M, Bertola G, Trevisan R, Bellini G. Antihypertensive treatment with enrasentan (SB 217242) in an animal model of hypertension and hyperinsulinemia. J Cardiovasc Pharmacol 2002;39:488-494.
15. Cosenzi A, Bernobich E, Plazzotta N, Seculin P, Bellini G. Bosentan reduces blood pressure and renal and cardiac changes induced by high fructose diet in rats. J Hypertens 1999;17:1843-1848.
16. Cosenzi A, Sacerdote A, Plazzotta N et al. Losartan normalizes blood pressure and reverses renal and cardiac changes in rats on high fructose diet. High Blood Press 1998;7:151-155.
17. Douglas SA, Ohlstein EH. ET-1 promotes neointima formation after balloon angioplasty in the rat. J Cardiovasc Pharmacol 1993;22(Suppl 8):S371-S373.
18. Ebihara I, Nakamura T, Tomino Y, Koide H. Effect of a specific endothelin receptor A antagonist and an angiotensin-converting enzyme inhibitor on glomerular mRNA levels for extracellular matrix components, metalloproteinases (MMP) and a tissue inhibitor of MMP in aminonucleoside nephrosis. Nephrol Dial Transplant 1997;12(5):1001-1006.
19. Ehrenreich H, Anderson RW, Fox CH et al. Endothelins, peptides with potent vasoactive properties, are produced by human macrophages. J Exp Med 1990;172:1741-1748.
20. Estrada V, Tellez MJ, Moya J, Fernandez-Durango R, Egido J, Cruz AF. High plasma levels of ET-1 and atrial natruretic peptide in patients with acute ischemic stroke. Am J Hypertens 1994;7:1085-1089.
21. Fattinger K, Funk C, Pantze M et al. The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: A potential mechanism for hepatic adverse reactions. Clin Pharmacol Ther 2001;69:223-231.
22. Ferri C, Properzi G, Santucci A. ET-1: A pathogenic factor in human diseases or a physiologist's curiosity? High Blood Press 1995;4:1-19.
23. Fukui M, Nakamura T, Ebihara I et al. Gene expression for endothelins and their receptor in glomeruli of diabetic rats. J Lab Clin Med 1993;122:149-156.
24. Giaid A, Yanagisawa M, Langleben D et al. Expression of ET-1 in the lungs of patients with pulmonary hypertension. N Engl J Med 1993;328:1732-1739.
25. B receptor antagonist ameliorates proteinuria and glomerular lesion in rats with proliferative nephritis. Kidney Int 1996;50(3):962-972.
26. Gomez-Garre D, Ruiz-Ortega M, Ortego M et al. Effects and interactions of ET-1 and angiotensin II on matrix protein expression and syntesis and mesangial cell growth. Hypertension 1996;27(4):885-892.
27. Gruentzig AR, Senning A, Siegenthaler WE. Non-operative dilatation of coronary artery stenosis-percutaneous transluminal coronary angioplasty. N Engl J Med 1979;301:61.
28. Gutierrez S, Palacios I, Egido J et al. ET-1 induces loss of proteoglycans and enhances fibronectin and collagen production in cultured rabbit synovial cells. Eur J Pharmacol 1996;302(1-3):191-197.
29. Haapaniemi E, Tatlisumak T, Hamel K et al. Plasma ET-1 levels neither increase nor correlate with neurological scores, stroke risk factors, or outcome in patients with ischemic stroke. Stroke 2000;31(3):720-725.
30. Harada H, Kazami J, Watanuki S et al. Ethenesulfonamide derivatives, a novel class of orally endothelin-A receptor antagonists. Chem Pharm Bull (Tokyo) 2001;49(5):606-612.
31. Hargrove GM, Dufresne J, Whiteside C, Muruve DA, Wong NC. Diabetes mellitus increases ET-1 gene transcription in rat kidney. Kidney Int 2000;58(4):1534-1545.
32. Hocher B, George I, Diekmann F et al. ETA receptor blockade induces fibrosis of the clipped kidney in two-kidney-one-clip renovascular hypertensive rats. J Hypertens 2000;18(12):1807-1814.
33. Hocher B, Thone-Reineke C, Rohmeiss P et al. ET-1 transgenic mice develop glomerulosclerosis, interstitial fibrosis, and renal cysts but not hypertension. J Clin Invest 1997;99(6):1380-1389.
34. Inoue A, Yanagisawa M, Kimura S et al. The human endothelin family: Three structurally and pharmacologically distinct isopeptides predicted by three separate genes. Proc Natl Acad Sci USA 1989;86:2863-2867.
35. A receptor. J Cardiovasc Pharmacol 1992;20:S11-S14.
36. Ito H, Hirata Y, Adachi S, et al. ET-1 is an autocrine/paracrine factor in the mechanism of angiotensin II-induced hypertrophy in cultured rat cardiomyocytes. J Clin Invest 1993;92:398-403.
37. Juvela S. Plasma endothelin concentrations after aneurysmal subarachnoid hemorrhage. J Neurosurg 2000;92(3):390-400.
38. Kawaguchi H, Sawa H, Yasuda H. Endothelin stimulates angiotensin I to angiotensin II conversion in cultured pulmonary artery endothelial cells. J Mol Cell Cardiol 1990;22:839-842.
39. Khan MA, Dashwood MR, Mumtaz FH, Thompson CS, Mikhailidis DP, Morgan RJ. Upregulation of endothelin A receptor sites in the rabbit diabetic kidney; potential Relevance to the early pathogenesis of diabetic nephropathy. Nephron 1999;83:261-267.
40. Kohno M, Horio T, Ikeda M, et al. Angiotensin II stimulates ET-1 secretion in cultured rat mesangial cells. Kidney Int 1992;42:860-866.
41. Kojima H, Yamao J, Tsujimoto T, Takaya A, Fukui H. Mixed endothelin receptor antagonist, SB 209670, decreases portal pressure in biliary cirrhotic rats in vivo by reducing portal venous system resistance. J Hepatol 2000;32:43-50.
42. Krum H, Viskoper RJ, Lacourciere Y, Budde M, Charlon V. The effect of an endothelin receptor antagonists, bosentan, on blood pressure in patients with essential hypertension. N Engl J Med 1998;338:784-790.
43. Löffler BM. Endothelin converting enzyme inhibitors: Current status and perspectives. J Cardiovasc Pharmacol 2000;35(Suppl 2):S79-S82.
44. Lüscher TF. Endothelin. J Cardiovasc Pharmacol 1991;18(Suppl 10):15-22.
45. Lüscher TF, Barton M. Endothelins and endothelin receptor antagonists. Therapeutic considerations for a novel class of cardiovascular drugs. Circulation 2000;102:2434-2440
46. Maruyama S, Hirayama C, Yamamoto S, et al. Hyperendothelinemia and 1CG clearance in alcoholic and non-alcoholic cirrhosis. Dig Dis Sci 2002;47:773-777.
47. Moller S, Henriksen JH Endothelins in chronic liver disease. Scand J Clin Lab Invest 1996;56:481-490.
48. Moreau P. Endothelin in hypertension: A role for receptor antagonists? Cardiovasc Res 1998;39:534-542.
49. Niwa Y, Nagata N, Oka M, et al. Production of nitric oxide from endothelial cells by 31-amino-acid-length ET-1, a novel vasoconstrictive product by human chymase. Life Sci 2000;67(9):1103-1109.
50. Ohlstein EH, Nambi P, Lago A, et al. Nonpeptide endothelin receptor antagonists. VI: Pharmacological characterization of SB 217242, a potent and highly bioavailable endothelin receptor antagonist. J Pharmacol Exp Ther 1996;276:609-615.
51. Packer M, Caspi A, Charlon V, et al. Multicenter, double-blind, placebo-controlled study of long-term endothelin blockade with bosentan in chronic heart failure: Results of the REACH-1 trial. Circulation 1998;98:1-3.
52. Pandey AS, Stewart DJ, Cernacek P, Dawood F, Wen WH, Liu P. Chronic ET-1 blockade preserves myocardial contractility in dilated cardiomyopathy. J Cardiovasc Pharmacol 1998;31(Suppl 1):S306-S308.
53. Pinzani M, Milani S, De Franco R, et al. Endothelin 1 is over expressed in human cirrhotic liver and exerts multiple effects on activated stellate cells. Gastroenterology 1996;110:534-548.
54. Poo JL, Jimenez W, Munoz R, et al. Chronic blockade of endothelin receptors in cirrhotic rats: Hepatic and hemodynamic effects. Gastroenterology 1999;116(1):161-167.
55. Rizvi MA, Katwa L, Spadone DP, Myers PR. The effects of ET-1 on collagen type I and type III synthesis in cultured porcine coronary artery vascular smooth muscle cells. J Mol Cell Cardiol 1996;28(2):243-252.
56. Rubin JL, Badesch DB, Barst RJ. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002;346:896-903.
57. Sessa WC, Kaw S, Hecker M, et al. The biosynthesis of ET-1 by human polymorphonuclear leukocytes. Biochem Biophys Res Commun 1991;174:613-618.
58. B receptor antagonist, in portal hypertensive rats. Hepatology 1998;28:655-659.
59. Spinella MJ, Malik AB, Everitt J, Andersen TT. Design and synthesis of a specific endothelin 1 antagonist: Effects on pulmonary vasoconstriction. Proc Natl Acad Sci 1991;88:7443-7446.
60. Sütsch G, Kiowski W, Yan XW, et al. Short-term oral endothelin-receptor antagonist therapy in conventionally treated patients with symptomatic severe chronic heart failure. Circulation 1998;98:2262-2268.
61. Torre-Amione G, Young JB, Colucci WS, Lewis B, Kobrin I, Pratt CM. A prospective, randomized, doubleblind, placebo-controlled, multicenter study of the efficacy and safety of tezosentan in patients with acute decompensated heart failure (RITZ-2). Abs Book of 7th International Conference on Endothelin. Edinburg (U.K.) 16-19 September 2001;128.
62. Treinen KA, Louden C, Dennis MJ, Wier PJ. Developmental toxicity and toxicokinetics of two endothelin receptor antagonists in rats and rabbits. Teratology 1999;59(1):51-59.
63. Underwood DC, Bochnowicz S, Osborn RR, Luttmann MA, Hay DWP. Nonpeptide endothelin receptor antagonists. X Inhibition of ET-1- and hypoxia-induced pulmonary pressor responses in the guinea pig by the endothelin receptor antagonist, SB 217242. Pharmacology 1997;283(3):1130-1137.
64. Wagner OF, Christ G, Wojta J, et al. Polar secretion of ET-1 by cultured endothelial cells. J Biol Chem 1992;267:16066-16068.
65. B receptor mRNA after angioplasty-induced neointimal formation in the rat. Circ Res 1996;78:322-328.
66. Wei CM, Lerman A, Rodenheffer RJ, et al. Increased value of plasma ET-1 in patients with chronic heart failure. Circulation 1994;89:1580-1586.
67. Wei GZ, Zhang J, Sheng SL, Ai HX, Ma JC, Lui HB. Increased plasma ET-1 in patients with acute cerebral infarction and actions on pial arterioles of rat. Chin Med J 1993;106:917-921.
68. Willette RN, Anderson KM, Nelson AH, et al. Enrasentan improves survival, limits left ventricular remodeling, and preserves myocardial performance in hypertensive cardiac hypertrophy and dysfunction. J Cardiovasc Pharmacol 2001;38(4):606-617.
69. Willette RN, Minehart H, Ellison J, et al. Effects of endothelin receptor antagonism and angiotensin converting enzyme inhibition on cardiac and renal remodeling in the rat. J Cardiovasc Pharmacol 1998;31(Suppl 1):S277-S283.
70. Willette RN, Ohlstein EH, Pullen M, Sauermelch CF, Cohen A, Nambi P. Transient forebrain ischemia alters acutely ET receptor density and immunoreactivity in gerbil brain. Life Sci 1993;52:35-40.
71. Williamson DJ, Wallman LL, Jones R, et al. Hemodynamic effects of bosentan, an endothelin receptor antagonist, in patients with pulmonary hypertension. Circulation 2000;102(4):411-418.
72. A selective endothelin receptor antagonists. 1. Discovery of A 127722. J Med Chem 1996;39:1039-1048.
73. Worth SJ, Woods M, Warner TD, Evans TW, Mitchell JA. Endogenously released ET-1 from human pulmonary artery smooth muscle promotes cellular proliferation. Am J Respir Cell Mol Biol 2001;25:104-110.
74. Xu S, Denton CP, Holmes A, Dashwood MR, Abraham DJ, Black CM. Endothelins: Effect on matrix biosynthesis and proliferation in normal and scleroderma fibroblasts. J Cardiovasc Pharmacol 1998;31(Suppl 1):S360-S363.
75. Yamashita K, Kataoka Y, Niwa M, et al. Increased production of ETs in the hippocampus of stroke-prone spontaneously hypertensive rats following transient forebrain ischemia: Histochemical evidence. Cell Mol Neurobiol 1993;13:15-23.
76. Yanagisawa M, Kurihara H, Kimura S, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988;332:411-415.
77. Yang LC, Wang F, Liu M. A study of an endothelin antagonist from a Chinese anti-snake venom medicinal herb. J Cardiovasc Pharmacol 1998;31:S249-S250.
78. Zhang Y, Oliver JR, Horowitz JD. Endothelin B receptor mediated vasoconstriction induced by endothelin A receptor antagonist. Cardiovasc Res 1998;39:665-673.
79. Ziv I, Fleminger G, Dyaldetti R, Achiron A, Melamed E, Sokolovsky M. Increased plasma ET-1 in acute ischemic stroke. Stroke 1992;23:1014-1016.
80. Zoja C, Morigi M, Figliuzzi M, Bruzzi I, Oldroyd S, Benigni A. Proximal tubular cell synthesis and secretion of ET-1 on challenge with albumin and other proteins. Am J Kidney Dis 1995;26:934-941.
81. Zolk O, Quattek J, Sitzler G, et al. Expression of ET-1, endothelin-converting enzyme, and endothelin receptor in chronic heart failure. Circulation 1999;99:2118-2123.